| Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study ES Siris, ST Harris, R Eastell, JR Zanchetta, S Goemaere, A Diez‐Perez, ... Journal of Bone and Mineral Research 20 (9), 1514-1524, 2005 | 361 | 2005 |
| A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin–treated patients with type 2 diabetes RM Bergenstal, J Rosenstock, RF Arakaki, MJ Prince, Y Qu, VP Sinha, ... Diabetes Care 35 (11), 2140-2147, 2012 | 139 | 2012 |
| Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes CM Apovian, RM Bergenstal, RM Cuddihy, Y Qu, S Lenox, MS Lewis, ... The American journal of medicine 123 (5), 468. e9-468. e17, 2010 | 137 | 2010 |
| Effects of exenatide plus rosiglitazone on β-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin RA DeFronzo, C Triplitt, Y Qu, MS Lewis, D Maggs, LC Glass Diabetes care 33 (5), 951-957, 2010 | 132 | 2010 |
| Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data Y Qu, SJ Jacober, Q Zhang, LL Wolka, JH DeVries Diabetes technology & therapeutics 14 (11), 1008-1012, 2012 | 130 | 2012 |
| Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study J Rosenstock, RM Bergenstal, TC Blevins, LA Morrow, MJ Prince, Y Qu, ... Diabetes care 36 (3), 522-528, 2013 | 104 | 2013 |
| Propensity score estimation with missing values using a multiple imputation missingness pattern (MIMP) approach Y Qu, I Lipkovich Statistics in medicine 28 (9), 1402-1414, 2009 | 103 | 2009 |
| The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety DW Stovall, WH Utian, MLS Gass, Y Qu, D Muram, M Wong, L Plouffe Jr Menopause 14 (3), 510-517, 2007 | 95 | 2007 |
| Small area estimation under a restriction J Wang, WA Fuller, Y Qu Survey methodology 34 (1), 29, 2008 | 74 | 2008 |
| Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass RR Recker, D Kendler, CP Recknor, TW Rooney, EM Lewiecki, WH Utian, ... Bone 40 (4), 843-851, 2007 | 72 | 2007 |
| Sample size calculation for the Wilcoxon–Mann–Whitney test adjusting for ties YD Zhao, D Rahardja, Y Qu Statistics in medicine 27 (3), 462-468, 2008 | 70 | 2008 |
| Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo … SL Schwartz, RE Ratner, DD Kim, Y Qu, LL Fechner, SM Lenox, ... Clinical therapeutics 30 (5), 858-867, 2008 | 64 | 2008 |
| Randomized, double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes … RM Bergenstal, H Lunt, E Franek, F Travert, J Mou, Y Qu, CJ Antalis, ... Diabetes, Obesity and Metabolism 18 (11), 1081-1088, 2016 | 49 | 2016 |
| Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis LC Glass, Y Qu, S Lenox, D Kim, JR Gates, R Brodows, M Trautmann, ... Current medical research and opinion 24 (3), 639-644, 2008 | 46 | 2008 |
| Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosis T Nakamura, JL Liu, H Morii, QR Huang, HM Zhu, Y Qu, E Hamaya, ... Journal of bone and mineral metabolism 24, 414-418, 2006 | 40 | 2006 |
| Basal insulin peglispro: overview of a novel long‐acting insulin with reduced peripheral effect resulting in a hepato‐preferential action SJ Jacober, MJ Prince, JM Beals, ML Hartman, Y Qu, H Linnebjerg, ... Diabetes, Obesity and Metabolism 18, 3-16, 2016 | 37 | 2016 |
| Quantifying the indirect treatment effect via surrogate markers Y Qu, M Case Statistics in medicine 25 (2), 223-231, 2006 | 37 | 2006 |
| The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial Y Qu, M Wong, D Thiebaud, JL Stock Current medical research and opinion 21 (12), 1955-1959, 2005 | 37 | 2005 |
| Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia T Dayspring, Y Qu, C Keech Metabolism 55 (7), 972-979, 2006 | 35 | 2006 |
| Estimation of group means when adjusting for covariates in generalized linear models Y Qu, J Luo Pharmaceutical statistics 14 (1), 56-62, 2015 | 31 | 2015 |
